Search

Your search keyword '"Lam, Carolyn S. P."' showing total 1,451 results
Start Over Author "Lam, Carolyn S. P."
1,451 results on '"Lam, Carolyn S. P."'

1. Insights on prevalence and incidence of anemia and rapid up-titration of oral heart failure treatment from the STRONG-HF study

Author

Čelutkienė, Jelena, Čerlinskaitė-Bajorė, Kamilė, Cotter, Gad, Edwards, Christopher, Adamo, Marianna, Arrigo, Mattia, Barros, Marianela, Biegus, Jan, Chioncel, Ovidiu, Cohen-Solal, Alain, Damasceno, Albertino, Diaz, Rafael, Filippatos, Gerasimos, Gayat, Etienne, Kimmoun, Antoine, Léopold, Valentine, Deniau, Benjamin, Metra, Marco, Novosadova, Maria, Pagnesi, Matteo, Pang, Peter S., Ponikowski, Piotr, Saidu, Hadiza, Sliwa, Karen, Takagi, Koji, Ter Maaten, Jozine M., Tomasoni, Daniela, Lam, Carolyn S. P., Voors, Adriaan A., Mebazaa, Alexandre, and Davison, Beth

Published
2024
Full Text
View/download PDF

2. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes

Author

Vaduganathan, Muthiah, Filippatos, Gerasimos, Claggett, Brian L., Desai, Akshay S., Jhund, Pardeep S., Henderson, Alasdair, Brinker, Meike, Kolkhof, Peter, Schloemer, Patrick, Lay-Flurrie, James, Viswanathan, Prabhakar, Lam, Carolyn S. P., Senni, Michele, Shah, Sanjiv J., Voors, Adriaan A., Zannad, Faiez, Rossing, Peter, Ruilope, Luis M., Anker, Stefan D., Pitt, Bertram, Agarwal, Rajiv, McMurray, John J. V., and Solomon, Scott D.

Published
2024
Full Text
View/download PDF

11. Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF

Author

Shen, Li, Dewan, Pooja, Ferreira, João Pedro, Cunningham, Jonathan W., Jhund, Pardeep S., Anand, Inder S., Chandra, Alvin, Chiang, Lu-May, Claggett, Brian, Desai, Akshay S., Gong, Jianjian, Lam, Carolyn S. P., Lefkowitz, Martin P., Maggioni, Aldo P., Martinez, Felipe, Packer, Milton, Redfield, Margaret M., Rouleau, Jean L., van Veldhuisen, Dirk J., Zannad, Faiez, Zile, Michael R., Solomon, Scott D., and McMurray, John J. V.

Published
2024
Full Text
View/download PDF

12. Author Correction: Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes

Author

Vaduganathan, Muthiah, Filippatos, Gerasimos, Claggett, Brian L., Desai, Akshay S., Jhund, Pardeep S., Henderson, Alasdair, Brinker, Meike, Kolkhof, Peter, Schloemer, Patrick, Lay-Flurrie, James, Viswanathan, Prabhakar, Lam, Carolyn S. P., Senni, Michele, Shah, Sanjiv J., Voors, Adriaan A., Zannad, Faiez, Rossing, Peter, Ruilope, Luis M., Anker, Stefan D., Pitt, Bertram, Agarwal, Rajiv, McMurray, John J. V., and Solomon, Scott D.

Published
2024
Full Text
View/download PDF

18. Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study

Author

Gerhardt, Teresa, Gerhardt, Louisa M S, Ouwerkerk, Wouter, Roth, Gregory A, Dickstein, Kenneth, Collins, Sean P, Cleland, John G F, Dahlstrom, Ulf, Tay, Wan Ting, Ertl, Georg, Hassanein, Mahmoud, Perrone, Sergio V, Ghadanfar, Mathieu, Schweizer, Anja, Obergfell, Achim, Filippatos, Gerasimos, Lam, Carolyn S P, Tromp, Jasper, and Angermann, Christiane E

Published
2023
Full Text
View/download PDF

19. Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

Author

Vardeny, Orly, Fang, James C., Desai, Akshay S., Jhund, Pardeep S., Claggett, Brian, Vaduganathan, Muthiah, de Boer, Rudolf A., Hernandez, Adrian F., Lam, Carolyn S. P., Inzucchi, Silvio E., Martinez, Felipe A., Kosiborod, Mikhail N., DeMets, David, O’Meara, Eileen, Zieroth, Shelley, Comin-Colet, Josep, Drozdz, Jaroslaw, Chiang, Chern-En, Kitakaze, Masafumi, Petersson, Magnus, Lindholm, Daniel, Langkilde, Anna Maria, McMurray, John J. V., and Solomon, Scott D.

Published
2023
Full Text
View/download PDF

20. Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

Author

Vardeny, Orly, Fang, James C., Desai, Akshay S., Jhund, Pardeep S., Claggett, Brian, Vaduganathan, Muthiah, de Boer, Rudolf A., Hernandez, Adrian F., Lam, Carolyn S. P., Inzucchi, Silvio E., Martinez, Felipe A., Kosiborod, Mikhail N., DeMets, David, O’Meara, Eileen, Zieroth, Shelley, Comin-Colet, Josep, Drozdz, Jaroslaw, Chiang, Chern-En, Kitakaze, Masafumi, Petersson, Magnus, Lindholm, Daniel, Langkilde, Anna Maria, McMurray, John J. V., and Solomon, Scott D.

Published
2022
Full Text
View/download PDF

21. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER

Author

Jhund, Pardeep S., Kondo, Toru, Butt, Jawad H., Docherty, Kieran F., Claggett, Brian L., Desai, Akshay S., Vaduganathan, Muthiah, Gasparyan, Samvel B., Bengtsson, Olof, Lindholm, Daniel, Petersson, Magnus, Langkilde, Anna Maria, de Boer, Rudolf A., DeMets, David, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Køber, Lars, Lam, Carolyn S. P., Martinez, Felipe A., Sabatine, Marc S., Shah, Sanjiv J., Solomon, Scott D., and McMurray, John J. V.

Published
2022
Full Text
View/download PDF

22. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial

Author

Inzucchi, Silvio E, Claggett, Brian L, Vaduganathan, Muthiah, Desai, Akshay S, Jhund, Pardeep S, de Boer, Rudolf A, Hernandez, Adrian F, Kosiborod, Mikhail N, Lam, Carolyn S P, Martinez, Felipe, Shah, Sanjiv J, Verma, Subodh, Han, Yaling, Kerr Saraiva, Jose F, Bengtsson, Olof, Petersson, Magnus, Langkilde, Anna Maria, McMurray, John J V, and Solomon, Scott D

Published
2022
Full Text
View/download PDF

28. Proteomics Identify Clinical Phenotypes and Predict Functional Outcomes in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF.

Author

deFilippi, Christopher R., Shah, Palak, Shah, Sanjiv J., Alemayehu, Wendimagegn, Lam, Carolyn S. P., Butler, Javed, Roessig, Lothar, O’Connor, Christopher M., Westerhout, Cynthia M., and Armstrong, Paul W.

Abstract

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome that may emerge from overlapping systemic processes associated with comorbidities. We assessed whether unique clusters of circulating proteins are associated with specific clinical characteristics and functional status at baseline and follow-up in a well-phenotyped cohort of patients with HFpEF. METHODS: We evaluated 368 proteins associated with cardiovascular disease and inflammation in prerandomization blood samples from 763 VITALITY-HFpEF (Vericiguat to Improve Physical Functioning in Daily Living Activities of Patients With HFpEF) participants who had a left ventricular ejection fraction ≥45% and a heart failure decompensation event within 6 months. Proteins were clustered, and their associations with clinical characteristics, baseline, and 24-week functional outcomes (Kansas City Cardiomyopathy Questionnaire Physical Limitation Score, 6-minute walk distance [6MWD], and Fried frailty phenotype) were estimated with linear regression. Elastic net regression was used to derive a proteomic summary composite to predict changes in 24-week functional outcomes. RESULTS: Four unique protein clusters were identified, containing 24, 66, 197, and 81 proteins. At baseline, 2 protein clusters with the hub proteins caspase-3 and Dickkopf-related protein 1 were associated with increased frailty, whereas the cluster with tumor necrosis factor receptor 1 as a hub protein was associated with lower Kansas City Cardiomyopathy Questionnaire Physical Limitation Score and shorter 6MWD. By contrast, the cluster with protein C as a hub protein was associated with less frailty and longer a 6MWD. The 24-week increase in 6MWD was negatively correlated with the protein cluster with caspase-3; the protein C cluster was correlated with less frailty at 24 weeks. The baseline proteomic summary composite predicted observed changes in Kansas City Cardiomyopathy Questionnaire Physical Limitation Score and 6MWD at 24 weeks (r=0.42 and 0.30; P<0.001 for both). CONCLUSIONS: Proteomics differentiate specific baseline functional traits associated with HFpEF and may facilitate phenotyping in a heterogeneous disease. These proteins also provide insights into the diverse pathophysiology of HFpEF and which patients may improve functional status during follow-up. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

Author

Packer, M, Anker, S, Butler, J, Filippatos, G, Pocock, S, Zannad, F, Ferreira, JP, Brueckmann, M, George, J, Jamal, W, Welty, FK, Palmer, M, Clayton, T, Parhofer, KG, Pedersen, TR, Greenberg, B, Konstam, MA, Lees, KR, Carson, P, Doehner, W, Miller, A, Haas, M, Pehrson, S, Komajda, M, Anand, I, Teerlink, J, Rabinstein, A, Steiner, T, Kamel, H, Tsivgoulis, G, Lewis, J, Freston, J, Kaplowitz, N, Mann, J, Petrie, J, Perrone, S, Nicholls, S, Janssens, S, Bocchi, E, Giannetti, N, Verma, S, Zhang, J, Spinar, J, Seronde, M-F, Boehm, M, Merkely, B, Chopra, V, Senni, M, Taddi, S, Tsutsui, H, Choi, D-J, Chuquiure, E, La Rocca, HPB, Ponikowski, P, Juanatey, JRG, Squire, I, Januzzi, J, Pina, I, Bernstein, R, Cheung, A, Green, J, Kaul, S, Lam, C, Lip, G, Marx, N, McCullough, P, Mehta, C, Rosenstock, J, Sattar, N, Scirica, B, Shah, S, Wanner, C, Aizenberg, D, Cartasegna, L, Colombo Berra, F, Colombo, H, Fernandez Moutin, M, Glenny, J, Alvarez Lorio, C, Anauch, D, Campos, R, Facta, A, Fernandez, A, Ahuad Guerrero, R, Lobo Márquez, L, Leon de la Fuente, RA, Mansilla, M, Hominal, M, Hasbani, E, Najenson, M, Moises Azize, G, Luquez, H, Guzman, L, Sessa, H, Amuchástegui, M, Salomone, O, Perna, E, Piskorz, D, Sicer, M, Perez de Arenaza, D, Zaidman, C, Nani, S, Poy, C, Resk, J, Villarreal, R, Majul, C, Smith Casabella, T, Sassone, S, Liberman, A, Carnero, G, Caccavo, A, Berli, M, Budassi, N, Bono, J, Alvarisqueta, A, Amerena, J, Kostner, K, Hamilton, A, Begg, A, Beltrame, J, Colquhoun, D, Gordon, G, Sverdlov, A, Vaddadi, G, Wong, J, Coller, J, Prior, D, Friart, A, Leone, A, Vervoort, G, Timmermans, P, Troisfontaines, P, Franssen, C, Sarens, T, Vandekerckhove, H, Van De Borne, P, Chenot, F, De Sutter, J, De Vuyst, E, Debonnaire, P, Dupont, M, Pereira Dutra, O, Canani, LH, Vieira Moreira, MdC, de Souza, W, Backes, LM, Maia, L, De Souza Paolino, B, Manenti, ER, Saporito, W, Villaça Guimarães Filho, F, Franco Hirakawa, T, Saliba, LA, Neuenschwander, FC, de Freitas Zerbini, CA, Gonçalves, G, Gonçalves Mello, Y, Ascenção de Souza, J, Beck da Silva Neto, L, Bocchi, EA, Da Silveira, J, de Moura Xavier Moraes Junior, JB, de Souza Neto, JD, Hernandes, M, Finimundi, HC, Sampaio, CR, Vasconcellos, E, Neves Mancuso, FJ, Noya Rabelo, MM, Rodrigues Bacci, M, Santos, F, Vidotti, M, Simões, MV, Gomes, FL, Vieira Nascimento, C, Precoma, D, Helfenstein Fonseca, FA, Ribas Fortes, JA, Leães, PE, Campos de Albuquerque, D, Kerr Saraiva, JF, Rassi, S, Alves da Costa, FA, Reis, G, Zieroth, S, Dion, D, Savard, D, Bourgeois, R, Constance, C, Anderson, K, Leblanc, M-H, Yung, D, Swiggum, E, Pliamm, L, Pesant, Y, Tyrrell, B, Huynh, T, Spiegelman, J, Lavoie, J-P, Hartleib, M, Bhargava, R, Straatman, L, Virani, S, Costa-Vitali, A, Hill, L, Heffernan, M, Khaykin, Y, Ricci, J, Senaratne, M, Zhai, A, Lubelsky, B, Toma, M, Yao, L, McKelvie, R, Noronha, L, Babapulle, M, Pandey, A, Curnew, G, Lavoie, A, Berlingieri, J, Kouz, S, Lonn, E, Chehayeb, R, Zheng, Y, Sun, Y, Cui, H, Fan, Z, Han, X, Jiang, X, Tang, Q, Zhou, J, Zheng, Z, Zhang, X, Zhang, N, Zhang, Y, Shen, A, Yu, J, Ye, J, Yao, Y, Yan, J, Xu, X, Wang, Z, Ma, J, Li, Y, Li, S, Lu, S, Kong, X, Song, Y, Yang, G, Yao, Z, Pan, Y, Guo, X, Sun, Z, Dong, Y, Zhu, J, Peng, D, Yuan, Z, Lin, J, Yin, Y, Jerabek, O, Burianova, H, Fiala, T, Hubac, J, Ludka, O, Monhart, Z, Vodnansky, P, Zeman, K, Foldyna, D, Krupicka, J, Podpera, I, Busak, L, Radvan, M, Vomacka, Z, Prosecky, R, Cifkova, R, Durdil, V, Vesely, J, Vaclavik, J, Cervinka, P, Linhart, A, Brabec, T, Miklik, R, Bourhaial, H, Olbrich, H-G, Genth-Zotz, S, Kemala, E, Lemke, B, Böhm, M, Schellong, S, Rieker, W, Heitzer, T, Ince, H, Faghih, M, Birkenfeld, A, Begemann, A, Ghanem, A, Ujeyl, A, von Haehling, S, Dorsel, T, Bauersachs, J, Prull, M, Weidemann, F, Darius, H, Nickenig, G, Wilke, A, Sauter, J, Rauch-Kroehnert, U, Frey, N, Schulze, CP, König, W, Maier, L, Menzel, F, Proskynitopoulos, N, Ebert, H-H, Sarnighausen, H-E, Düngen, H-D, Licka, M, Stellbrink, C, Winkelmann, B, Menck, N, López-Sendón, JL, de la Fuente Galán, L, Delgado Jiménez, JF, Manito Lorite, N, Pérez de Juan Romero, M, Galve Basilio, E, Cereto Castro, F, González Juanatey, JR, Gómez, JJ, Sanmartín Fernández, M, Garcia-Moll Marimon, X, Pascual Figal, D, Bover Freire, R, Bonnefoy Cudraz, E, Jobbe Duval, A, Tomasevic, D, Habib, G, Isnard, R, Picard, F, Khanoyan, P, Dubois-Rande, J-L, Galinier, M, Roubille, F, Alexandre, J, Babuty, D, Delarche, N, Berneau, J-B, Girerd, N, Saxena, M, Rosano, G, Yousef, Z, Clifford, C, Arden, C, Bakhai, A, Boos, C, Jenkins, G, Travill, C, Price, D, Koenyves, L, Lakatos, F, Matoltsy, A, Noori, E, Zilahi, Z, Andrassy, P, Kancz, S, Simon, G, Sydo, T, Vorobcsuk, A, Kiss, RG, Toth, K, Szakal, I, Nagy, L, Barany, T, Nagy, A, Szolnoki, E, Chopra, VK, Mandal, S, Rastogi, V, Shah, B, Mullasari, A, Shankar, J, Mehta, V, Oomman, A, Kaul, U, Komarlu, S, Kahali, D, Bhagwat, A, Vijan, V, Ghaisas, NK, Mehta, A, Kashyap, J, Kothari, Y, TaddeI, S, Scherillo, M, Zacà, V, Genovese, S, Salvioni, A, Fucili, A, Fedele, F, Cosmi, F, Volpe, M, Mazzone, C, Esposito, G, Doi, M, Yamamoto, H, Sakagami, S, Oishi, S, Yasaka, Y, Tsuboi, H, Fujino, Y, Matsuoka, S, Watanabe, Y, Himi, T, Ide, T, Ichikawa, M, Kijima, Y, Koga, T, Yuda, S, Fukui, K, Kubota, T, Manita, M, Fujinaga, H, Matsumura, T, Fukumoto, Y, Kato, R, Kawai, Y, Hiasa, G, Kazatani, Y, Mori, M, Ogimoto, A, Inoko, M, Oguri, M, Kinoshita, M, Okuhara, K, Watanabe, N, Ono, Y, Otomo, K, Sato, Y, Matsunaga, T, Takaishi, A, Miyagi, N, Uehara, H, Takaishi, H, Urata, H, Kataoka, T, Matsubara, H, Matsumoto, T, Suzuki, T, Takahashi, N, Imamaki, M, Yoshitama, T, Saito, T, Sekino, H, Furutani, Y, Koda, M, Shinozaki, T, Hirabayashi, K, Tsunoda, R, Yonezawa, K, Hori, H, Yagi, M, Arikawa, M, Hashizume, T, Ishiki, R, Koizumi, T, Nakayama, K, Taguchi, S, Nanasato, M, Yoshida, Y, Tsujiyama, S, Nakamura, T, Oku, K, Shimizu, M, Suwa, M, Momiyama, Y, Sugiyama, H, Kobayashi, K, Inoue, S, Kadokami, T, Maeno, K, Kawamitsu, K, Maruyama, Y, Nakata, A, Shibata, T, Wada, A, Cho, H-J, Na, JO, Yoo, B-S, Choi, J-O, Hong, SK, Shin, J-H, Cho, M-C, Han, SH, Jeong, J-O, Kim, J-J, Kang, SM, Kim, D-S, Kim, MH, Llamas Esperon, G, Illescas Díaz, J, Fajardo Campos, P, Almeida Alvarado, J, Bazzoni Ruiz, A, Echeverri Rico, J, Lopez Alcocer, I, Valle Molina, L, Hernandez Herrera, C, Calvo Vargas, C, Padilla Padilla, FG, Rodriguez Briones, I, Chuquiure Valenzuela, EJJR, Aguilera Real, ME, Carrillo Calvillo, J, Alpizar Salazar, M, Cervantes Escárcega, JL, Velasco Sanchez, R, Al - Windy, N, van Heerebeek, L, Bellersen, L, Brunner-La Rocca, H-P, Post, J, Linssen, GCM, van de Wetering, M, Peters, R, van Stralen, R, Groutars, R, Smits, P, Yilmaz, A, Kok, WEM, Van der Meer, P, Dijkmans, P, Troquay, R, van Alem, AP, Van de Wal, R, Handoko, L, Westendorp, ICD, van Bergen, PFMM, Rensing, BJWM, Hoogslag, P, Kietselaer, B, Kragten, JA, den Hartog, FR, Alings, A, Danilowicz-Szymanowicz, L, Raczak, G, Piesiewicz, W, Zmuda, W, Kus, W, Podolec, P, Musial, W, Drelich, G, Kania, G, Miekus, P, Mazur, S, Janik, A, Spyra, J, Peruga, J, Balsam, P, Krakowiak, B, Szachniewicz, J, Ginel, M, Grzybowski, J, Chrustowski, W, Wojewoda, P, Kalinka, A, Zurakowski, A, Koc, R, Debinski, M, Fil, W, Kujawiak, M, Forys, J, Kasprzak, M, Krol, M, Michalski, P, Mirek-Bryniarska, E, Radwan, K, Skonieczny, G, Stania, K, Skoczylas, G, Madej, A, Jurowiecki, J, Firek, B, Wozakowska-Kaplon, B, Cymerman, K, Neutel, J, Adams, K, Balfour, P, Deswal, A, Djamson, A, Duncan, P, Hong, M, Murray, C, Rinde-Hoffman, D, Woodhouse, S, MacNevin, R, Rama, B, Broome-Webster, C, Kindsvater, S, Abramov, D, Barettella, M, Pinney, S, Herre, J, Cohen, A, Vora, K, Challappa, K, West, S, Baum, S, Cox, J, Jani, S, Karim, A, Akhtar, A, Quintana, O, Paukman, L, Goldberg, R, Bhatti, Z, Budoff, M, Bush, E, Potler, A, Delgado, R, Ellis, B, Dy, J, Fialkow, J, Sangrigoli, R, Ferdinand, K, East, C, Falkowski, S, Donahoe, S, Ebrahimi, R, Kline, G, Harris, B, Khouzam, R, Jaffrani, N, Jarmukli, N, Kazemi, N, Koren, M, Friedman, K, Herzog, W, Silva Enciso, J, Cheung, D, Grover-McKay, M, Hauptman, P, Mikhalkova, D, Hegde, V, Hodsden, J, Khouri, S, McGrew, F, Littlefield, R, Bradley, P, McLaurin, B, Lupovitch, S, Labin, I, Rao, V, Leithe, M, Lesko, M, Lewis, N, Lombardo, D, Mahal, S, Malhotra, V, Dauber, I, Banerjee, A, Needell, J, Miller, G, Paladino, L, Munuswamy, K, Nanna, M, McMillan, E, Mumma, M, Napoli, M, Nelson, W, O'Brien, T, Adlakha, A, Onwuanyi, A, Serota, H, Schmedtje, J, Paraschos, A, Potu, R, Sai-Sudhakar, C, Saltzberg, M, Sauer, A, Shah, P, Skopicki, H, Bui, H, Carr, K, Stevens, G, Tahirkheli, N, Tallaj, J, Yousuf, K, Trichon, B, Welker, J, Tolerico, P, Vest, A, Vivo, R, Wang, X, Abadier, R, Dunlap, S, Weintraub, N, Malik, A, Kotha, P, Zaha, V, Kim, G, Uriel, N, Greene, T, Salacata, A, Arora, R, Gazmuri, R, Kobayashi, J, Iteld, B, Vijayakrishnan, R, Dab, R, Mirza, Z, Marques, V, Nallasivan, M, Bensimhon, D, Peart, B, Saint-Jacques, H, Barringhaus, K, Contreras, J, Gupta, A, Koneru, S, Nguyen, V, Verma, Subodh, Dhingra, Nitish K, Butler, Javed, Anker, Stefan D, Ferreira, Joao Pedro, Filippatos, Gerasimos, Januzzi, James L, Lam, Carolyn S P, Sattar, Naveed, Peil, Barbara, Nordaby, Matias, Brueckmann, Martina, Pocock, Stuart J, Zannad, Faiez, and Packer, Milton

Published
2022
Full Text
View/download PDF

32. Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction

Author

McDowell, Kirsty, primary, Kondo, Toru, additional, Talebi, Atefeh, additional, Teh, Ken, additional, Bachus, Erasmus, additional, de Boer, Rudolf A., additional, Campbell, Ross T., additional, Claggett, Brian, additional, Desai, Ashkay S., additional, Docherty, Kieran F., additional, Hernandez, Adrian F., additional, Inzucchi, Silvio E., additional, Kosiborod, Mikhail N., additional, Lam, Carolyn S. P., additional, Martinez, Felipe, additional, Simpson, Joanne, additional, Vaduganathan, Muthiah, additional, Jhund, Pardeep S., additional, Solomon, Scott D., additional, and McMurray, John J. V., additional

Published
2024
Full Text
View/download PDF

36. Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE‐O trial.

Author

Gerstein, Hertzel C., Yang, Mu, Lee, Shun Fu, Branch, Kelley R. H., Del Prato, Stefano, Lam, Carolyn S. P., Lopes, Renato D., Pratley, Richard, Rosenstock, Julio, and Sattar, Naveed

Subjects
PANCREATIC acinar cells, MAJOR adverse cardiovascular events, REDUCING diets, TYPE 2 diabetes, SYSTOLIC blood pressure, ASPARTATE aminotransferase, INSULIN
Abstract

The article "Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE‐O trial" published in Diabetes, Obesity & Metabolism explores the impact of the GLP‐1 RA efpeglenatide on HbA1c levels in individuals with type 2 diabetes. The study found that efpeglenatide significantly reduced HbA1c levels by 1.46% within 3 months, along with other positive effects on weight, blood pressure, cholesterol levels, and other health markers. However, the analysis revealed that less than 12% of efpeglenatide's effect on HbA1c could be explained by its impact on weight loss and other nonglycaemic factors. The study suggests that the glycaemic effect of efpeglenatide is primarily due to its incretin-related effects, with weight loss playing a modest role. [Extracted from the article]

Published
2024
Full Text
View/download PDF

37. Toward a Universal Definition of Etiologies in Heart Failure : Categorizing Causes and Advancing Registry Science

Author

Agarwal, Anubha, Tromp, Jasper, Almahmeed, Wael, Angermann, Christiane, Chandramouli, Chanchal, Cho, Hyunjai, Choi, Don-Ju, Damasceno, Albertino, Filippatos, Gerasimos, Fonarow, Gregg C., Harikrishnan, Sivadasanpillai, Lund, Lars, Masoudi, Fred, Mensah, George A., Pathan, Asad, Perel, Pablo, Pinto, Fausto, Ribeiro, Antonio Luiz, Rich, Stuart, Sakata, Yasuhiko, Sliwa, Karen, Sundström, Johan, Wong, Renee, Yancy, Clyde, Yiu, Kelvin, Zhang, Jian, Zhang, Yuhui, Lam, Carolyn S. P., Roth, Gregory A., Agarwal, Anubha, Tromp, Jasper, Almahmeed, Wael, Angermann, Christiane, Chandramouli, Chanchal, Cho, Hyunjai, Choi, Don-Ju, Damasceno, Albertino, Filippatos, Gerasimos, Fonarow, Gregg C., Harikrishnan, Sivadasanpillai, Lund, Lars, Masoudi, Fred, Mensah, George A., Pathan, Asad, Perel, Pablo, Pinto, Fausto, Ribeiro, Antonio Luiz, Rich, Stuart, Sakata, Yasuhiko, Sliwa, Karen, Sundström, Johan, Wong, Renee, Yancy, Clyde, Yiu, Kelvin, Zhang, Jian, Zhang, Yuhui, Lam, Carolyn S. P., and Roth, Gregory A.

Abstract

Heart failure (HF) is a well-described final common pathway for a broad range of diseases however substantial confusion exists regarding how to describe, study, and track these underlying etiologic conditions. We describe (1) the overlap in HF etiologies, comorbidities, and case definitions as currently used in HF registries led or managed by members of the global HF roundtable; (2) strategies to improve the quality of evidence on etiologies and modifiable risk factors of HF in registries; and (3) opportunities to use clinical HF registries as a platform for public health surveillance, implementation research, and randomized registry trials to reduce the global burden of noncommunicable diseases. Investment and collaboration among countries to improve the quality of evidence in global HF registries could contribute to achieving global health targets to reduce noncommunicable diseases and overall improvements in population health.

Published
2024
Full Text
View/download PDF

38. Symptoms and signs in patients with heart failure: association with 3-month hospitalisation and mortality

Author

Ali, Mohammad Rizwan, Lam, Carolyn S. P., Strömberg, Anna, Hand, Simon P. P., Booth, Sarah, Zaccardi, Francesco, Squire, Iain, Mccann, Gerry P., Khunti, Kamlesh, Lawson, Claire Alexandra, Ali, Mohammad Rizwan, Lam, Carolyn S. P., Strömberg, Anna, Hand, Simon P. P., Booth, Sarah, Zaccardi, Francesco, Squire, Iain, Mccann, Gerry P., Khunti, Kamlesh, and Lawson, Claire Alexandra

Abstract

Objectives To determine the association between symptoms and signs reported in primary care consultations following a new diagnosis of heart failure (HF), and 3-month hospitalisation and mortality.Design Nested case-control study with density-based sampling.Setting Clinical Practice Research Datalink, linked to hospitalisation and mortality (1998-2020).Participants Database cohort of 86 882 patients with a new HF diagnosis. In two separate analyses for (1) first hospitalisation and (2) death, we compared the 3-month history of symptoms and signs in cases (patients with HF with the event), with their respective controls (patients with HF without the respective event, matched on diagnosis date (+/- 1 month) and follow-up time). Controls could be included more than once and later become a case.Main outcome measures All-cause, HF and non-cardiovascular disease (non-CVD) hospitalisation and mortality.Results During a median follow-up of 3.22 years (IQR: 0.59-8.18), 56 677 (65%) experienced first hospitalisation and 48 146 (55%) died. These cases were matched to 356 714 and 316 810 HF controls, respectively. For HF hospitalisation, the strongest adjusted associations were for symptoms and signs of fluid overload: pulmonary oedema (adjusted OR 3.08; 95% CI 2.52, 3.64), shortness of breath (2.94; 2.77, 3.11) and peripheral oedema (2.16; 2.00, 2.32). Generic symptoms also showed significant associations: depression (1.50; 1.18, 1.82), anxiety (1.35; 1.06, 1.64) and pain (1.19; 1.10, 1.28). Non-CVD hospitalisation had the strongest associations with chest pain (2.93; 2.77, 3.09), fatigue (1.87; 1.73, 2.01), general pain (1.87; 1.81, 1.93) and depression (1.59; 1.44, 1.74).Conclusions In the primary care HF population, routinely recorded cardiac and non-specific symptoms showed differential risk associations with hospitalisation and mortality., Funding Agencies|National Institute for Health Research (NIHR) Advanced Fellowship [NIHR300111]; NIHR Applied Research Collaboration East Midlands (ARCEM); NIHR Leicester Biomedical Research Centre (BRC)

Published
2024
Full Text
View/download PDF

39. Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study.

Author

Hoeper, Marius M., Oerke, Britta, Wissmüller, Max, Leuchte, Hanno, Opitz, Christian, Halank, Michael, Seyfarth, Hans-Juergen, Baldus, Stephan, Bauersachs, Johann, Böhm, Michael, Ghofrani, Hossein-Ardeschir, Konstantinides, Stavros, Olsson, Karen M., Wachter, Rolf, Lam, Carolyn S. P., Aminossadati, Behnaz, and Rosenkranz, Stephan

Published
2024
Full Text
View/download PDF

40. Applications of SGLT2 inhibitors beyond glycaemic control.

Author

O'Hara, Daniel V., Lam, Carolyn S. P., McMurray, John J. V., Yi, Tae Won, Hocking, Samantha, Dawson, Jessica, Raichand, Smriti, Januszewski, Andrzej S., and Jardine, Meg J.

Subjects
*SODIUM-glucose cotransporters, *CANAGLIFLOZIN, *SODIUM-glucose cotransporter 2 inhibitors, *GLYCEMIC control, *TYPE 2 diabetes, *DISEASE risk factors, *DIASTOLIC blood pressure
Abstract

Sodium–glucose cotransporter 2 (SGLT2) inhibitors were initially developed for their glucose-lowering effects and have shown a modest glycaemic benefit in people with type 2 diabetes mellitus (T2DM). In the past decade, a series of large, robust clinical trials of these therapies have demonstrated striking beneficial effects for various care goals, transforming the chronic disease therapeutic landscape. Cardiovascular safety studies in people with T2DM demonstrated that SGLT2 inhibitors reduce cardiovascular death and hospitalization for heart failure. Subsequent trials in participants with heart failure with reduced or preserved left ventricular ejection fraction demonstrated that SGLT2 inhibitors have beneficial effects on heart failure outcomes. In dedicated kidney outcome studies, SGLT2 inhibitors reduced the incidence of kidney failure among participants with or without diabetes. Post hoc analyses have suggested a range of other benefits of these drugs in conditions as diverse as metabolic dysfunction-associated steatotic liver disease, kidney stone prevention and anaemia. SGLT2 inhibitors have a generally favourable adverse effect profile, although patient selection and medication counselling remain important. Concerted efforts are needed to better integrate these agents into routine care and support long-term medication adherence to close the gap between clinical trial outcomes and those achieved in the real world. Here, the authors discuss the beneficial effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors for a range of clinical outcomes beyond glucose lowering, including kidney and cardiovascular protection. They also discuss the need for implementation and adherence initiatives to help translate the benefits of these agents into real-world clinical outcomes. Key points: Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of kidney disease progression in people with or without diabetes as well as the risk of acute kidney injury and hyperkalaemia. SGLT2 inhibitors reduce the risk of cardiovascular death and heart failure hospitalization among people with type 2 diabetes mellitus and have beneficial effects on key heart failure outcomes irrespective of diabetes status or left ventricular ejection fraction. SGLT2 inhibitors modestly lower systolic and diastolic blood pressure without a significant increase in risk of hypotensive episodes and have modest benefits for weight loss. Other benefits of SGLT2 inhibitors include improvements in liver outcomes in people with metabolic dysfunction-associated steatotic liver disease, reduced risk of symptomatic kidney stone events, improvements in anaemia outcomes and potential reductions in the risk of new-onset atrial fibrillation and new-onset diabetes. SGLT2 inhibitors have a generally favourable adverse effect profile but are associated with increased risk of genital mycotic infections and a small increased risk of diabetic ketoacidosis; they should be used with caution in people with unstable volume status owing to the risk of hypovolaemia. Prescription of SGLT2 by clinicians and patient adherence are suboptimal despite strong evidence for the efficacy and cost-effectiveness of these therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF.

Author

Dewan, Pooja, Li Shen, Pedro Ferreira, João, Jhund, Pardeep S., Anand, Inder S., Chandra, Alvin, Lu-May Chiang, Claggett, Brian, Desai, Akshay S., Jianjian Gong, Lam, Carolyn S. P., Lefkowitz, Martin P., Maggioni, Aldo P., Martinez, Felipe, Packer, Milton, Redfield, Margaret M., Rouleau, Jean L., van Veldhuisen, Dirk J., Zannad, Faiez, and Zile, Michael R.

Published
2024
Full Text
View/download PDF

42. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study

Author

Kosiborod, Mikhail, Cavender, Matthew A, Wilding, John P, Khunti, Kamlesh, Norhammar, Anna, Birkeland, Kåre, Jørgensen, Marit Eika, Holl, Reinhard W., Lam, Carolyn SP, Gulseth, Hanne Løvdal, Carstensen, Bendix, Bollow, Esther, Franch-Nadal, Josep, García Rodríguez, Luis Alberto, Karasik, Avraham, Tangri, Navdeep, Kohsaka, Shun, Kim, Dae Jung, Shaw, Jonathan, Arnold, Suzanne, Goh, Su-Yen, Fenici, Peter, Bodegård, Johan, Chen, Hungta, Surmont, Filip, Blak, Betina T., Wittbrodt, Eric T., Saathoff, Matthias, Noguchi, Yusuke, Tan, Donna, Williams, Maro, Lee, Hye Won, Greenbloom, Maya, Kaidanovich-Beilin, Oksana, Yeo, Khung Keong, Bee, Yong Mong, Khoo, Joan, Koong, Agnes, Lau, Yee How, Gao, Fei, Tan, Wee Boon, Kadir, Hanis Abdul, Ha, Kyoung Hwa, Lee, Jinhee, Chodick, Gabriel, Melzer-Cohen, Cheli, Whitlock, Reid, Cea-Soriano, Lucia, Cantero, Oscar Fernándex, Menzin, Jordan A., Guthrie, Matthew, Ilomaki, Jennie, Magliano, Dianna, Lam, Carolyn S P, Jørgensen, Marit E, Birkeland, Kåre I, Holl, Reinhard W, Shaw, Jonathan E, Ilomäki, Jenni, Chiang, Chern-En, Thuresson, Marcus, and Wittbrodt, Eric

Published
2020
Full Text
View/download PDF

43. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study

Author

Tromp, Jasper, Bamadhaj, Sahiddah, Cleland, John G F, Angermann, Christiane E, Dahlstrom, Ulf, Ouwerkerk, Wouter, Tay, Wan Ting, Dickstein, Kenneth, Ertl, Georg, Hassanein, Mahmoud, Perrone, Sergio V, Ghadanfar, Mathieu, Schweizer, Anja, Obergfell, Achim, Lam, Carolyn S P, Filippatos, Gerasimos, and Collins, Sean P

Published
2020
Full Text
View/download PDF

44. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction

Author

Vardeny, Orly, primary, Desai, Akshay S., additional, Jhund, Pardeep S., additional, Fang, James C., additional, Claggett, Brian, additional, de Boer, Rudolf A., additional, Hernandez, Adrian F., additional, Inzucchi, Silvio E., additional, Kosiborod, Mikhail N., additional, Lam, Carolyn S. P., additional, Martinez, Felipe A., additional, Shah, Sanjiv J., additional, Mc Causland, Finnian R., additional, Petrie, Mark C., additional, Vaduganathan, Muthiah, additional, McMurray, John J. V., additional, and Solomon, Scott D., additional

Published
2024
Full Text
View/download PDF

45. Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial

Author

Gerstein, Hertzel C., primary, Mian, Rajibul, additional, Ramasundarahettige, Chinthanie, additional, Branch, Kelley R. H., additional, Del Prato, Stefano, additional, Lam, Carolyn S. P., additional, Lopes, Renato D., additional, Pratley, Richard, additional, Rosenstock, Julio, additional, and Sattar, Naveed, additional

Published
2023
Full Text
View/download PDF

46. Nurse-led home-based detection of cardiac dysfunction by ultrasound: results of the CUMIN pilot study

Author

Tromp, Jasper, primary, Sarra, Chenik, additional, Nidhal, Bouchahda, additional, Mejdi, Ben Messaoud, additional, Zouari, Fourat, additional, Hummel, Yoran, additional, Mzoughi, Khadija, additional, Kraiem, Sondes, additional, Fehri, Wafa, additional, Gamra, Habib, additional, Lam, Carolyn S P, additional, Mebazaa, Alexandre, additional, and Addad, Faouzi, additional

Published
2023
Full Text
View/download PDF

49. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure

Author

Santema, Bernadet T., Chan, Michelle M. Y., Tromp, Jasper, Dokter, Martin, van der Wal, Haye H., Emmens, Johanna E., Takens, Janny, Samani, Nilesh J., Ng, Leong L., Lang, Chim C., van der Meer, Peter, ter Maaten, Jozine M., Damman, Kevin, Dickstein, Kenneth, Cleland, John G., Zannad, Faiez, Anker, Stefan D., Metra, Marco, van der Harst, Pim, de Boer, Rudolf A., van Veldhuisen, Dirk J., Rienstra, Michiel, Lam, Carolyn S. P., and Voors, Adriaan A.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results